Sintilimab for treating progressive multifocal leukoencephalopathy caused by human polyomavirus 2 virus infection following allogeneic hematopoietic cell transplantation: a case report
Sintilimab, a PD-1 inhibitor, might be used to treat PML in patients with hematologic malignancies undergoing allo-HSCT, which needs further investigation.
Authors
- Xinchuan Chen (ORCID: https://orcid.org/0000-0001-9292-9623)
- Qinyu Liu (ORCID: https://orcid.org/0000-0001-9194-8320)
- Xushu Zhong (ORCID: https://orcid.org/0000-0001-5194-1394)
- Xuelian Jin
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Hematology
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1080/16078454.2025.2458932
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00